China Licensing

Briding the gap for Western life sciences companies to Asia


With the idea to have representatives for licensing transactions in Europe and in China, FCF Life Sciences formed a joint venture with Yafo Capital, Ltd. in 2019. Together, we form a unique team to address the needs of our European and Asian clients. Our aim is to facilitate and guarantee a smooth partnering process.

Facts on Yafo Capital, Ltd.

  • Shanghai based advisory firm
  • Established network and access to leading 200+ Pharma and MedTech companies in Asia
  • Team of 20+ professionals with banking and healthcare background
  • ~20 completed transactions within the last five years


Company presentations
Meeting requests
Assets presented
FCF co-organizes, together with its partner YAFO Capital, the “ACCESS CHINA Forum”, which will be held online 4x per year.

ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable business development opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations.


FCF Biotech Venture Capital Monitor – USA 08/2023 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 08/2023”.

The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector.

As of the end of August 2023, we identify the following current VC trends in the US-Biotech sector:

  • In 2023, overall Biotech funding in the USA has reached USD 13,752m
  • Compared to August 2022 the financing volume decreased by more than 40% (23,189m vs. 13,752m)
  • The top 5 deals exceed USD 270m each, the largest transaction amounted to USD 401m with ElevateBio
  • Cellares has the highest transaction Volume of USD 255m in August, followed by Genesis Therapeutics USD 224m and ADARx Pharmaceuticals USD 200m
  • Flagship Pioneers (USA) is leading the Top 5 Investors (by deal volume), followed by ARCH Venture Partners (USA) and OrbiMed (USA)
  • As an indication oncology records the highest investment activity

To access the full report, please click here.

By Mathias Klozenbücher, Johannes Link and Marcel-Louis Christou.


If you are interested in exploring China licensing opportunities, please contact us: